These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11579119)

  • 1. Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial.
    Scott AM; Lee FT; Hopkins W; Cebon JS; Wheatley JM; Liu Z; Smyth FE; Murone C; Sturrock S; MacGregor D; Hanai N; Inoue K; Yamasaki M; Brechbiel MW; Davis ID; Murphy R; Hannah A; Lim-Joon M; Chan T; Chong G; Ritter G; Hoffman EW; Burgess AW; Old LJ
    J Clin Oncol; 2001 Oct; 19(19):3976-87. PubMed ID: 11579119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts.
    Lee FT; Rigopoulos A; Hall C; Clarke K; Cody SH; Smyth FE; Liu Z; Brechbiel MW; Hanai N; Nice EC; Catimel B; Burgess AW; Welt S; Ritter G; Old LJ; Scott AM
    Cancer Res; 2001 Jun; 61(11):4474-82. PubMed ID: 11389078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma.
    Scott AM; Liu Z; Murone C; Johns TG; MacGregor D; Smyth FE; Lee FT; Cebon J; Davis ID; Hopkins W; Mountain AJ; Rigopoulos A; Hanai N; Old LJ
    Cancer Immun; 2005 Feb; 5():3. PubMed ID: 15723450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871.
    Liu Z; Lee FT; Hanai N; Smyth FE; Burgess AW; Old LJ; Scott AM
    Cancer Immun; 2002 Oct; 2():13. PubMed ID: 12747758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
    Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
    J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma.
    Forero A; Shah J; Carlisle R; Triozzi PL; LoBuglio AF; Wang WQ; Fujimori M; Conry RM
    Cancer Biother Radiopharm; 2006 Dec; 21(6):561-8. PubMed ID: 17257071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.
    Wong JY; Thomas GE; Yamauchi D; Williams LE; Odom-Maryon TL; Liu A; Esteban JM; Neumaier M; Dresse S; Wu AM; Primus FJ; Shively JE; Raubitschek AA
    J Nucl Med; 1997 Dec; 38(12):1951-9. PubMed ID: 9430476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant antibodies against ganglioside expressed on tumor cells.
    Hanai N; Nakamura K; Shitara K
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S13-7. PubMed ID: 10950141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potential of chimeric anti-(ganglioside GD3) antibody KM871: antitumor activity in xenograft model of melanoma and effector function analysis.
    Kanazawa J; Ohta S; Shitara K; Fujita F; Fujita M; Hanai N; Akinaga S; Okabe M
    Cancer Immunol Immunother; 2000 Jul; 49(4-5):253-8. PubMed ID: 10941908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of antibody dose on the imaging and biodistribution of indium-111 9.2.27 anti-melanoma monoclonal antibody.
    Carrasquillo JA; Abrams PG; Schroff RW; Reynolds JC; Woodhouse CS; Morgan AC; Keenan AM; Foon KA; Perentesis P; Marshall S
    J Nucl Med; 1988 Jan; 29(1):39-47. PubMed ID: 3335926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial.
    Tempero M; Leichner P; Baranowska-Kortylewicz J; Harrison K; Augustine S; Schlom J; Anderson J; Wisecarver J; Colcher D
    Clin Cancer Res; 2000 Aug; 6(8):3095-102. PubMed ID: 10955789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial experience evaluating 90yttrium-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a phase I radioimmunotherapy trial.
    Wong JY; Williams LE; Yamauchi DM; Odom-Maryon T; Esteban JM; Neumaier M; Wu AM; Johnson DK; Primus FJ; Shively JE
    Cancer Res; 1995 Dec; 55(23 Suppl):5929s-5934s. PubMed ID: 7493373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A mouse/human chimeric anti-(ganglioside GD3) antibody with enhanced antitumor activities.
    Shitara K; Kuwana Y; Nakamura K; Tokutake Y; Ohta S; Miyaji H; Hasegawa M; Hanai N
    Cancer Immunol Immunother; 1993 Jun; 36(6):373-80. PubMed ID: 8500110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.
    Scott AM; Wiseman G; Welt S; Adjei A; Lee FT; Hopkins W; Divgi CR; Hanson LH; Mitchell P; Gansen DN; Larson SM; Ingle JN; Hoffman EW; Tanswell P; Ritter G; Cohen LS; Bette P; Arvay L; Amelsberg A; Vlock D; Rettig WJ; Old LJ
    Clin Cancer Res; 2003 May; 9(5):1639-47. PubMed ID: 12738716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250.
    Steffens MG; Boerman OC; de Mulder PH; Oyen WJ; Buijs WC; Witjes JA; van den Broek WJ; Oosterwijk-Wakka JC; Debruyne FM; Corstens FH; Oosterwijk E
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3268s-3274s. PubMed ID: 10541374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake.
    Scott AM; Lee FT; Jones R; Hopkins W; MacGregor D; Cebon JS; Hannah A; Chong G; U P; Papenfuss A; Rigopoulos A; Sturrock S; Murphy R; Wirth V; Murone C; Smyth FE; Knight S; Welt S; Ritter G; Richards E; Nice EC; Burgess AW; Old LJ
    Clin Cancer Res; 2005 Jul; 11(13):4810-7. PubMed ID: 16000578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioimmunoimaging in malignant melanoma with 111In-labeled monoclonal antibody 96.5.
    Murray JL; Rosenblum MG; Sobol RE; Bartholomew RM; Plager CE; Haynie TP; Jahns MF; Glenn HJ; Lamki L; Benjamin RS
    Cancer Res; 1985 May; 45(5):2376-81. PubMed ID: 3986779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunospecific saturable clearance mechanisms for indium-111-labeled anti-melanoma monoclonal antibody 96.5 in humans.
    Murray JL; Lamki LM; Shanken LJ; Blake ME; Plager CE; Benjamin RS; Schweighardt S; Unger MW; Rosenblum MG
    Cancer Res; 1988 Aug; 48(15):4417-22. PubMed ID: 3390837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rhenium-186-labeled chimeric antibody NR-LU-13: pharmacokinetics, biodistribution and immunogenicity relative to murine analog NR-LU-10.
    Weiden PL; Breitz HB; Seiler CA; Bjorn MJ; Ratliff BA; Mallett R; Beaumier PL; Appelbaum JW; Fritzberg AR; Salk D
    J Nucl Med; 1993 Dec; 34(12):2111-9. PubMed ID: 8254397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.